Tag: Horizon Therapeutics
Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE
Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in the treatment of systemic lupus erythematosus (SLE) ... Read More
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology ... Read More
Glenmark Pharmaceuticals gets FDA final approval for Buphenyl generic
Glenmark Pharmaceuticals said that it has bagged final approval for Sodium Phenylbutyrate Tablets USP, 500 mg by the US Food and Drug Administration (FDA). The ... Read More
Horizon Therapeutics to acquire Viela Bio for $3bn to grow rare disease portfolio
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 ... Read More